NasdaqGS:NBIXBiotechs
INGREZZA and CRENESSITY Sales Beat Might Change the Case for Investing in Neurocrine Biosciences (NBIX)
Neurocrine Biosciences reported its third-quarter 2025 financial results, achieving revenue of US$794.9 million and net income of US$209.5 million, both surpassing prior-year figures and analyst forecasts.
A key insight from the quarter is that strong sales growth in INGREZZA and CRENESSITY, coupled with promising progress in late-stage clinical trials, reflects ongoing momentum in both product demand and the company's research pipeline.
We'll assess how this earnings beat, driven by...